Intellia Therapeutics (NTLA) Institutional Ownership
13F filers reported holding 22.4% of Intellia Therapeutics (NTLA) shares as of Sep 30, 2026, across 157 filers.
- Held by 13F filers
- 22.4%
- Sep 30, 2026
- 13F filers
- 157
- quarter ended Sep 30, 2026
- 13F value
- $379.2M
- 31.4M shares
- Quarter's fund flow
- Mild accumulation
- 16 new · 19 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | LEONARD JOHN M. | President and CEO | Disposed · Open-market sale | 9,000 | $11.99 | ↗ |
| Oct 26, 2026 | Marantz Jing L. | EVP, Chief Medical Officer | Acquired · Grant / award | 199,822 | — | ↗ |
| Oct 26, 2026 | Marantz Jing L. | EVP, Chief Medical Officer | Acquired · Grant / award | 275,061Stock Option (right to buy) | — | ↗ |
| Oct 2, 2026 | Dube Michael P | VP, Chief Accounting Officer | Disposed · Open-market sale | 1,864 | $12.43 | ↗ |
| Aug 21, 2026 | LEONARD JOHN M. | President and CEO | Disposed · Open-market sale | 2,785 | $13.00 | ↗ |
| Aug 20, 2026 | LEONARD JOHN M. | President and CEO | Disposed · Open-market sale | 19,890 | $12.60 | ↗ |
| Jul 22, 2026 | Dulac Edward J III | EVP, Chief Financial Officer | Disposed · Open-market sale | 8,111 | $11.25 | ↗ |
| Jul 2, 2026 | Dulac Edward J III | EVP, Chief Financial Officer | Disposed · Open-market sale | 4,677 | $18.00 | ↗ |
| Jul 1, 2026 | Dube Michael P | VP, Chief Accounting Officer | Disposed · Open-market sale | 2,641 | $16.78 | ↗ |
| Jun 9, 2026 | GOODMAN JESSE | director | Acquired · Grant / award | 9,200 | — | ↗ |
| Jun 9, 2026 | GOODMAN JESSE | director | Acquired · Grant / award | 13,300Stock Option (right to buy) | — | ↗ |
| Jun 9, 2026 | CHASE WILLIAM J | director | Acquired · Grant / award | 9,200 | — | ↗ |
| Jun 9, 2026 | CHASE WILLIAM J | director | Acquired · Grant / award | 13,300Stock Option (right to buy) | — | ↗ |
| Jun 9, 2026 | Verwiel Frank | director | Acquired · Grant / award | 9,200 | — | ↗ |
| Jun 9, 2026 | Verwiel Frank | director | Acquired · Grant / award | 13,300Stock Option (right to buy) | — | ↗ |
| Jun 9, 2026 | Keresty Georgia | director | Acquired · Grant / award | 9,200 | — | ↗ |
| Jun 9, 2026 | Keresty Georgia | director | Acquired · Grant / award | 13,300Stock Option (right to buy) | — | ↗ |
| Jun 9, 2026 | Goff Brian | director | Acquired · Grant / award | 9,200 | — | ↗ |
| Jun 9, 2026 | Goff Brian | director | Acquired · Grant / award | 13,300Stock Option (right to buy) | — | ↗ |
| Jun 9, 2026 | Cohen Fred E | director | Acquired · Grant / award | 9,200 | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Intellia Therapeutics do institutions hold?
13F filers reported holding 22.4% of Intellia Therapeutics' shares as of Sep 30, 2026, across 157 filers.
How many 13F filers hold Intellia Therapeutics?
Intellia Therapeutics was held by 157 13F filers as of Sep 30, 2026.
Not investment advice.

